title: Preclinical assessment of the neutralizing capacity of antivenoms produced in six Latin American countries against medically-relevant Bothrops snake venoms.
abstract: Species of the genus Bothrops induce the vast majority of snakebite envenomings in Latin America. A preclinical study was performed in the context of a regional network of public laboratories involved in the production, quality control and development of antivenoms in Latin America. The ability of seven polyspecific antivenoms, produced in Argentina, Brazil, Peru, Bolivia, Colombia and Costa Rica, to neutralize lethal, hemorrhagic, coagulant, defibrinogenating and myotoxic activities of the venoms of Bothrops neuwiedi (diporus) (Argentina), Bothrops jararaca (Brazil), B. neuwiedi (mattogrossensis) (Bolivia), Bothrops atrox (Peru and Colombia) and Bothrops asper (Costa Rica) was assessed using standard laboratory tests. Despite differences in the venom mixtures used in the immunization of animals for the production of these antivenoms, a pattern of extensive cross-neutralization was observed between these antivenoms and all the venoms tested, with quantitative differences in the values of effective doses. This study reveals the capacity of these antivenoms to neutralize, in preclinical tests, homologous and heterologous Bothrops venoms in Central and South America, and also highlight quantitative differences in the values of Median Effective Doses (ED50s) between the various antivenoms.
authors.affiliation: Instituto Clodomiro Picado, Universidad de Costa Rica, 1000 San José, Costa Rica.
authors.forename: A
authors.initials: A
authors.lastname: Segura
authors.forename: M C
authors.initials: MC
authors.lastname: Castillo
authors.forename: V
authors.initials: V
authors.lastname: Núñez
authors.forename: A
authors.initials: A
authors.lastname: Yarlequé
authors.forename: L R C
authors.initials: LR
authors.lastname: Gonçalves
authors.forename: M
authors.initials: M
authors.lastname: Villalta
authors.forename: C
authors.initials: C
authors.lastname: Bonilla
authors.forename: M
authors.initials: M
authors.lastname: Herrera
authors.forename: M
authors.initials: M
authors.lastname: Vargas
authors.forename: M
authors.initials: M
authors.lastname: Fernández
authors.forename: M Y
authors.initials: MY
authors.lastname: Yano
authors.forename: H P
authors.initials: HP
authors.lastname: Araújo
authors.forename: M A A
authors.initials: MA
authors.lastname: Boller
authors.forename: P
authors.initials: P
authors.lastname: León
authors.forename: B
authors.initials: B
authors.lastname: Tintaya
authors.forename: I S
authors.initials: IS
authors.lastname: Sano-Martins
authors.forename: A
authors.initials: A
authors.lastname: Gómez
authors.forename: G P
authors.initials: GP
authors.lastname: Fernández
authors.forename: P
authors.initials: P
authors.lastname: Geoghegan
authors.forename: H G
authors.initials: HG
authors.lastname: Higashi
authors.forename: G
authors.initials: G
authors.lastname: León
authors.forename: J M
authors.initials: JM
authors.lastname: Gutiérrez
mesh_terms: D000818:Animals; D000997:Antivenins / Q000276:immunology*; D001777:Blood Coagulation / Q000187:drug effects; D017837:Bothrops / Q000502:physiology*; D003402:Creatine Kinase / Q000097:blood; D003435:Crotalid Venoms / Q000009:adverse effects / Q000276:immunology*; D004353:Drug Evaluation, Preclinical; D005260:Female; D005342:Fibrinolysis / Q000187:drug effects; D006470:Hemorrhage / Q000139:chemically induced; D007155:Immunologic Factors / Q000276:immunology*; D007843:Latin America; D007928:Lethal Dose 50; D008297:Male; D051379:Mice; D018482:Muscle, Skeletal / Q000187:drug effects / Q000201:enzymology; D009220:Myositis / Q000139:chemically induced; D009500:Neutralization Tests / Q000379:methods*
chemical_list: D000997:Antivenins; D003435:Crotalid Venoms; D007155:Immunologic Factors; D003402:Creatine Kinase